Dacarbazine and tamoxifen in patients with advanced melanoma: An effective therapy option?

被引：0
|
作者：
Rass, K
Seiter, S
Uhl, K
Petzoldt, D
Tilgen, W
机构：
[1] DEPT DERMATOL,HOMBURG,GERMANY
[2] UNIV SAARLAND,D-6600 SAARBRUCKEN,GERMANY
[3] UNIV HEIDELBERG,DEPT DERMATOL,D-6900 HEIDELBERG,GERMANY
来源：
EUROPEAN JOURNAL OF CANCER | 1997年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1170 / 1170
页数：2
相关论文
共 50 条
  • [1] THERAPY FOR METASTATIC MELANOMA - EFFECTIVE COMBINATION OF DACARBAZINE, CARMUSTINE, CISPLATIN AND TAMOXIFEN
    FIERRO, MT
    BERTERO, M
    NOVELLI, M
    APPINO, A
    DOVEIL, GC
    COLONNA, S
    BERNENGO, MG
    MELANOMA RESEARCH, 1993, 3 (02) : 127 - 131
  • [2] Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients
    Sileni, VC
    Nortilli, R
    Aversa, SML
    Paccagnella, A
    Medici, M
    Corti, L
    Favaretto, AG
    Cetto, GL
    Monfardini, S
    MELANOMA RESEARCH, 2001, 11 (02) : 189 - 196
  • [3] A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
    Middleton M.R.
    Lorigan P.
    Owen J.
    Ashcroft L.
    Lee S.M.
    Harper P.
    Thatcher N.
    British Journal of Cancer, 2000, 82 (6) : 1158 - 1162
  • [4] Docetaxel in combination with dacarbazine in patients with advanced melanoma
    Bafaloukos, D
    Aravantinos, G
    Fountzilas, G
    Stathopoulos, G
    Gogas, H
    Samonis, G
    Briasoulis, E
    Mylonakis, N
    Skarlos, DV
    Kosmidis, P
    ONCOLOGY, 2002, 63 (04) : 333 - 337
  • [5] Immunomodulatory effect of tamoxifen in combination with CCNU, cisplatinum, and dacarbazine in melanoma patients
    Hadjikirova, M
    Peytcheva, E
    Boeva, M
    EXPERIMENTAL ONCOLOGY, 1998, 20 (3-4): : 248 - 251
  • [6] Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma
    Creagan, ET
    Suman, VJ
    Dalton, RJ
    Pitot, HC
    Long, HJ
    Veeder, MH
    Vukov, AM
    Rowland, KM
    Krook, JE
    Michalak, JC
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) : 1884 - 1890
  • [7] Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?
    Klee, Gina
    Hagelstein, Victoria
    Kurzhals, J. K.
    Zillikens, Detlef
    Terheyden, Patrick
    Langan, Ewan A.
    MELANOMA RESEARCH, 2022, 32 (05) : 360 - 365
  • [8] A randomized phase III study comparing decarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
    Middleton, MR
    Lorigan, P
    Owen, J
    Ashcroft, L
    Lee, SM
    Harper, P
    Thatcher, N
    BRITISH JOURNAL OF CANCER, 2000, 82 (06) : 1158 - 1162
  • [9] Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A Southwest Oncology Group Study
    Margolin, KA
    Liu, PY
    Flaherty, LE
    Sosman, JA
    Walker, MJ
    Smith, JW
    Fletcher, WS
    Weiss, GR
    Unger, JM
    Sondak, VK
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) : 664 - 669
  • [10] Rituximab as a therapeutic option for patients with advanced melanoma
    Winkler, Julia K.
    Schiller, Matthias
    Bender, Carolin
    Enk, Alexander H.
    Hassel, Jessica C.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (06) : 917 - 924
12345